SCDAA 46th Annual National Convention has ended

Create Your Own Event

SCDAA 46th Annual National Convention

Celebrating Diversity Within the Sickle Cell Community: Commitment, Innovation, Practice

1:15pm EDT

Virtual Reality as an Adjunct Pain Management Therapy Constellation C

1:55pm EDT

The Opioid Crisis and Nursing Ramifications Constellation C

2:35pm EDT

The Opioid Crisis- Non opioid Pain Management Treatment Options Constellation C

11:30am EDT

Healing the Healer Provider Session Constellation C

3:15pm EDT

Effect Of Long Term Treatment With Sc411 On Sickle Cell Crisis Rate In Children With Sickle Cell Disease Constellation C

3:30pm EDT

Compassionate-Use Voxelotor (GBT440) For Up To 2 Years In Patients With Severe Sickle Cell Disease And Life-Threatening Comorbidities Constellation C

3:45pm EDT

Crizanlizumab 5.0 Mg/Kg Increased the Time to First On-Treatment Sickel Cell Pain Crisis (SCPC) and the Likelihood of not Experiencing SCPC While on Treatment: Subgroup Analyses of the Phase 2 Sustain Study Constellation C

4:00pm EDT

Parent and Youth Barriers to Hydroxyurea Adherence in Adolescents with Sickle Cell Disease Constellation C

4:15pm EDT

Sickle Cell Patients with Leg Ulcers have a Pro-Thrombotic Profile Constellation C

4:30pm EDT

Crizanlizumab Treatment is Not Asoociated with the Development of Proteinuria and Hematuria in Patients with Sickle Cell Disease: Sustain Study Safety Analysis Constellation C

4:45pm EDT

Genome Editing to Fix the Sickle Cell Disease Causing Variant in Sickle Cell Patient Hematopoietic Stem Cells Constellation C

5:00pm EDT

Correction of the Sickle Mutation in Hematopoietic Stem/Progenitor Cells with CRISPR/Cas9: The Berkeley/UCSF/UCLA Sickle Cell Clinical Translation Project Constellation C

5:15pm EDT

The Clinical-Stage SGC Stimulator Olinciguat Prevents Increase Of Plasma Biomarkers Of Intravascular Inflammation And Suppresses Leukocyte-Endothelial Interactions In Tnfa-Treated Mice Constellation C